CS
APGE

Candriam SCA’s Apogee Therapeutics APGE Stock Holding History

Candriam SCA’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
79,684
-143,857
-64% -$13M 0.05% 285
2026
Q1 		$18.8M Buy
223,541
+32,223
+17% +$2.34M 0.1% 203
2025
Q4 		$14.4M Buy
191,318
+65,237
+52% +$4.11M 0.07% 221
2025
Q3 		$5.01M Buy
+126,081
New +$4.81M 0.03% 368
2025
Q1 		– Sell
-85,661
Closed -$3.88M – 678
2024
Q4 		$3.88M Sell
85,661
-4,339
-5% -$221K 0.02% 394
2024
Q3 		$5.29M Hold
90,000
– – 0.03% 353
2024
Q2 		$3.54M Hold
90,000
– – 0.02% 394
2024
Q1 		$5.98M Buy
+90,000
New +$3.93M 0.04% 314

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Candriam SCA's APGE Position: Q2 2026 in Review

Candriam SCA reduced its Apogee Therapeutics (APGE) stake by 64% in Q2 2026, selling an estimated $13M and leaving 79,684 shares worth $10.6M. The position accounts for 0.05% of the portfolio, ranked #285.

Candriam SCA first reported a position in APGE in Q1 2024 and has held it in 8 quarters since. The position peaked at $18.8M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Candriam SCA held 79,684 shares of Apogee Therapeutics worth $10.6M as of Q2 2026.
  • Candriam SCA sold 143,857 Apogee Therapeutics shares in Q2 2026, an estimated $13M.
  • Apogee Therapeutics made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #285 holding.
  • Candriam SCA first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Candriam SCA's Apogee Therapeutics position peaked at $18.8M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.